BCL2 and neoplasm: Overall, pan Bcl-2 family inhibition with ABT-263 or specific Bcl-xL inhibition with A-1331852 and radiotherapy significantly decreased tumor growth compared with drug or radiotherapy alone (Fig. 4B) and significantly extended time to tumor tripling (Fig. 4C).